Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
| ▸ | FBP1 | P09467 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL739541 | 0.82 | KAT2B (0.71) | KAT2BLMNAHCAR3MAPTALDH1A1 | |
| SCHEMBL18075204 | 0.78 | HCAR3 (0.67) | KAT2BLMNAHCAR3MAPTALDH1A1 | |
| SCHEMBL28183325 | 0.78 | HCAR3 (0.86) | LMNAHCAR3MAPTALDH1A1PTGER4 | |
| SCHEMBL1958584 | 0.78 | MAPT (0.75) | KAT2BLMNAHCAR3MAPTALDH1A1 | |
| SCHEMBL7745470 | 0.77 | ALDH1A1 (0.66) | KAT2BLMNAHCAR3MAPTALDH1A1 | |
| SCHEMBL1420938 | 0.77 | HCAR3 (0.58) | KAT2BLMNAHCAR3MAPTALDH1A1 | |
| SCHEMBL15984906 | 0.76 | KAT2B (0.74) | KAT2BLMNAHCAR3MAPTALDH1A1 | |
| SCHEMBL6024481 | 0.75 | MAPT (0.51) | KAT2BLMNAHCAR3MAPTALDH1A1 | |
| SCHEMBL6023064 | 0.74 | HCAR3 (0.50) | LMNAHCAR3MAPTALDH1A1PTGER4 | |
| SCHEMBL15774665 | 0.74 | MAPT (0.87) | LMNAHCAR3MAPTALDH1A1PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7138420-B2 | Substituted benzimidazole compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-11-21 | — | — | US | disclosed |
| US-20050203158-A1 | Substituted benzimidazole compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-09-15 | — | — | US | disclosed |
| EP-1529046-A1 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-05-11 | — | — | EP | disclosed |
| WO-2004014905-A1 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203158-A1 | Substituted benzimidazole compounds | ITK, BLK, SBK1 | KAT2B 2532/4885LMNA 2269/4885HCAR3 1724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.